Jascayd (nerandomilast)

Where it stands

Jascayd (nerandomilast) is authorised in the EU. The European Commission decision of 15 July 2026 granted the marketing authorisation to Boehringer Ingelheim International GmbH. The CHMP positive opinion came earlier, on 21 May 2026, so the decision followed the opinion by 55 days.

The authorised indications cover two populations of adults: Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF). The records list both as indications and give no further wording, such as restrictions, concomitant-therapy conditions or lines of treatment. The full scope is in the product information.

In the US, the records show an FDA approval on 19 December 2025 under NDA220449, for a tablet formulation. It is labelled a new indication under a separate NDA, with priority review. Two US entries for Jascayd are listed as approved, but the records do not say how they differ, so no conclusion should be drawn about the US label. The US approval came about five months before the CHMP opinion.

Regulatory pathway and designations

The EU records show the standard sequence: a CHMP opinion, then an EC decision. The records do not say whether the procedure used accelerated assessment, conditional marketing authorisation or exceptional circumstances. They also give no orphan status. Any such feature should be checked against the EPAR and the Union Register.

The only EU designation recorded is additional monitoring. This is a regulatory label, not a finding that the product is unsafe. It usually applies to newly authorised active substances and to products with limited long-term data. Such products carry an inverted black triangle in the product information, with a standard statement encouraging reporting of suspected adverse reactions.

In the US, the FDA review was designated priority review. The records give no PDUFA date, review timeline or other FDA designations, so none are assumed here.

Safety and pharmacovigilance

The records contain no safety data. They have no adverse-event profile, contraindications, warnings, risk management plan content or post-authorisation commitments. Nothing can be said about the benefit-risk balance from this dataset.

The only pharmacovigilance-relevant fact is the additional monitoring status. In practice, healthcare professionals and patients are encouraged to report suspected adverse reactions through national systems. Authorities and the company usually scrutinise such products more closely in early commercial use. Details on safety, any additional risk minimisation measures and planned studies are in the SmPC, the EPAR and the RMP summary.

What to watch

Publication of the EPAR and the final SmPC will show the exact wording of the two indications, the dosing and the safety information. They will also show whether any conditions or post-authorisation obligations apply.

Because the EU decision is very recent, national steps such as launch, pricing and reimbursement decisions would follow. The records contain no information on these, and none is assumed.

It would also help to clarify how the two US entries relate to the NDA and the indications, and to compare US and EU labels once the EU text is available. The records do not cover this, and further regulatory milestones such as variations or label updates are not recorded.